Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans
European Journal of Clinical Microbiology & Infectious Diseases · 2024
DOI: 10.1007/s10096-024-04799-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Alina Nussbaumer-Pröll und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Antifungal Agents, Microbial Sensitivity Tests, Pulmonary Surfactants, Candida albicans. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Purpose
This study investigates how surfactants affect the in-vitro anti-infective efficacy of micafungin, caspofungin, anidulafungin, and amphotericin B in treating pulmonary mycoses.
Methods
MIC values for antifungal agents were determined against Candida krusei (now Pichia kudriavzevii ) ATCC 6258, Candida albicans ATCC 90028, and 18 clinical isolates using the broth microdilution method in RPMI medium, following EUCAST recommendations. MIC assays included testing with and without Curosurf® surfactant at 1 mg/mL for C. krusei ATCC 6258 and all C. krusei isolates. Subsequent Time-kill studies in Sabouraud broth involved testing both C. albicans ATCC 90028 and C. krusei ATCC 6258 strains at concentrations equal their respective MIC values, with and without surfactant, using all four antifungals. CFU/mL were assessed at multiple time points up to 24 h. TKCs with different surfactant concentrations for C. krusei ATCC 6258 and mini-TKCs at various concentrations relative to the MIC of C. krusei isolates and the reference strain were conducted with micafungin, anidulafungin, and caspofungin.
Results
MIC results showed that 1 µg/mL surfactant reduced killing of micafungin and anidulafungin against C. krusei , while caspofungin was unaffected. Amphotericin B's MIC decreased by half. TKCs demonstrated significant effects of surfactant on micafungin and anidulafungin against C. krusei , with complete abolition of anidulafungin's activity against C. albicans .
Conclusion
This in-vitro study highlights the concentration-dependent inhibitory effect of surfactant on antifungal activity against C. krusei and, to some extent, C. albicans , necessitating further clinical validation for invasive lung mycoses treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. markus.zeitlinger@meduniwien.ac.at.
Förderung
- Medical University of Vienna
Zitieren
APA
Nussbaumer-Pröll, A., Matzneller, P., Eberl, S., & Zeitlinger, M. (2024). Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04799-7
Vancouver
Nussbaumer-Pröll A, Matzneller P, Eberl S, Zeitlinger M. Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04799-7
BibTeX
@article{NussbaumerPrll2024,
author = {Nussbaumer-Pröll, Alina and Matzneller, Peter and Eberl, Sabine and Zeitlinger, Markus},
title = {Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
doi = {10.1007/s10096-024-04799-7}
}
EUVIMED